Best peptides for joint pain and arthritis: what the evidence shows

Joint pain is several problems that share a symptom. Osteoarthritis is cartilage wear with changes in the underlying bone and inflammation of the joint lining; cartilage has no nerves, so the pain comes from bone and synovium. Inflammatory arthritis, rheumatoid or psoriatic, is immune driven and belongs to rheumatology. Tendinopathy is disorganized collagen and new blood vessel growth in a tendon that hurts under load. A ligament sprain is an acute injury that heals over weeks. These respond to different things, and the peptide evidence maps onto only one of them.

The rodent models behind BPC-157 and TB-500 are acute injuries in young animals: a cut Achilles tendon, a transected collateral ligament, a crushed muscle, a fresh skin wound. Those heal over weeks anyway, and the peptides sped them up. Osteoarthritis in a 55 year old knee is a degenerative process over years with no clean injury to repair. Neither compound page lists a rodent osteoarthritis model, and KPV has a single mouse arthritis study that was inflammatory rather than degenerative.

BPC-157 is the most used compound for this, and its page rates the tendon, ligament and muscle evidence as moderate on animal data and the joint pain evidence as weak. The animal work is extensive: faster healing and stronger tendon-to-bone reattachment in cut rat Achilles tendons, improved ligament healing, restored function after muscle crush with local or systemic dosing, and some fracture data in rats and rabbits. Nearly all of it is from one lab in Zagreb.

The human evidence for joints is one small series using intra-articular injection for knee pain, which reported reduced pain with no control group and was never followed by a trial. That is the entire human joint dataset. Reported community doses are 250 to 500 mcg once or twice daily, injected subcutaneously as close to the injury as practical for 4 to 8 weeks; protocols list 500 mcg twice daily for acute injuries and 250 to 500 mcg once daily for chronic tendon problems. The compound page is specific that nobody should inject into a tendon or joint capsule without clinical training. It also lists corticosteroid injections as a caution, since steroid shots weaken tendon tissue, and blood thinners, since the peptide's effects on clotting are not understood. It remains unapproved and WADA prohibited.

TB-500 is the synthetic fragment of thymosin beta-4, which regulates actin and lets cells migrate into a wound. The relevant evidence is rodent and equine tendon and ligament work plus long veterinary use in racehorses, which the compound page rates as moderate for soft tissue injury. There is no human trial of the fragment for any musculoskeletal purpose; the phase 2 human trials of thymosin beta-4 were eye drops of the full protein. What people report first is less stiffness and better range of motion at one to two weeks, with injury recovery judged at four to six. Community protocols load at 2 to 2.5 mg twice weekly for 4 to 6 weeks then drop to 2 mg every one to two weeks, injected anywhere convenient because it works systemically.

GHK-Cu is on joint lists because it drives collagen synthesis, but its page lists no joint or tendon data of any kind. Its evidence is topical skin trials and animal wound healing, where it stimulates both collagen production and the enzymes that clear damaged collagen. Injectable use at 1 to 2 mg daily has no human data, stings, and carries a copper caution. For joints the rationale is a mechanism borrowed from skin.

The BPC-157 and TB-500 stack, nicknamed the Wolverine stack, is how most people use the two together, and BPC-157 vs TB-500 covers the differences.

The only randomized trials with joint pain as an endpoint belong to the GLP-1 class, and they are weight loss trials. In STEP 9, people with obesity and knee osteoarthritis took semaglutide 2.4 mg weekly for 68 weeks and lost roughly 14 percent of body weight. Their WOMAC pain score improved by about 42 points on a 100 point scale against about 28 on placebo. The mechanism is mostly mechanical: each kilogram of body weight loads the knee by roughly four kilograms per step, so ten kilograms off is forty kilograms less through the joint with every stride.

Retatrutide has a dedicated phase 3 trial, TRIUMPH-4, in knee osteoarthritis with obesity. Lilly's 2026 topline reported weight loss with pain improvement, but it is a sponsor press release, not a published paper. Lilly plans to file for approval in the first quarter of 2027, so approval is not expected before late 2027 at the earliest, and the extra safety signal versus tirzepatide is a heart rate increase. Retatrutide vs tirzepatide compares the two.

The benefit applies to people carrying excess weight; a lean person with osteoarthritis gets nothing from it. And rapid weight loss takes lean mass with it, including the quadriceps that protect the knee, which is why GLP-1 muscle loss and resistance training belong in the same conversation.

The compound pages give the pattern for BPC-157: reduced pain and swelling in the first week, better range of motion and load tolerance at weeks two to four, and a plateau at weeks four to eight. TB-500 users describe less stiffness at one to two weeks and judge recovery at three to six. Those timelines come from community reports, and for pain they need a discount, because pain is the most placebo responsive outcome in medicine. Osteoarthritis trials routinely see 20 to 30 percent improvement in the placebo injection arm, so an uncontrolled report of feeling better means less here than for almost any other goal.

The fix is to measure. A pain score out of ten at a set time of day and a function test like time to climb a flight of stairs, recorded at baseline and at four and eight weeks, turns an impression into a number. If the number has not moved by eight weeks, the compound page's own advice is to stop.

For osteoarthritis, the treatments with trial evidence are strength training, particularly the quadriceps for the knee, weight loss where it applies, physiotherapy, topical and oral anti-inflammatories, and short term corticosteroid injections, with surgery for end stage joints. For tendinopathy it is progressive loading over months. Inflammatory arthritis needs a rheumatologist, and the KPV page lists adding another anti-inflammatory on top of a TNF blocker as an untested caution.

Two interactions matter here. Corticosteroid injections weaken tendon tissue, which works against what BPC-157 is being used for, and the compound page says to talk to whoever gave the shot. NSAIDs are fine alongside BPC-157, which protected the stomach lining from NSAID damage in rodents. Where a peptide fits is as an adjunct after the diagnosis is clear, with a measurable endpoint and a stop date. How to buy peptides and are peptides safe cover sourcing and risk.

Community practice for BPC-157 is a subcutaneous injection as close to the injury as is practical, though rodent studies show benefit with systemic dosing too. Subcutaneous means into the fat under the skin, not into the joint, the tendon or the muscle. The intra-articular knee series was done by clinicians with imaging guidance, and injecting into a joint capsule at home risks infection in a space that does not clear it well.

Peptide injection sites covers subcutaneous technique, rotation and the sites that work near a shoulder, elbow or knee. Peptides for inflammation picks up the inflammatory side of the same question, and the GLOW stack page covers the version that adds GHK-Cu.